Project Grant R44AI152657

Novobiotic Pharmaceuticals, LLC received a $4.5 million Project Grant award from the Defense Health Agency to conduct late-stage preclinical development of the antibiotic teixobactin through April 2026. The funding supports research under the Military Medical Research and Development program, which aims to develop medical solutions for battlefield injuries and infectious diseases. Specifically, the award will allow Novobiotic to advance teixobactin, initially discovered using its iChip...

This $600,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a stable, aerosolizable dry powder formulation of D29 mycobacteriophages for the treatment of tuberculosis (TB). The award recipient, Via Therapeutics, LLC, a for-profit pharmaceutical research and development company, will utilize thin-film freeze-drying technology to create the phage-based dry...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $802,798 to The Research Foundation For The State University Of New York to develop a novel class of antibiotics called Biamyxins (BMX) to target multidrug-resistant Gram-negative bacterial infections. The key products and services to be delivered include: Optimization of the lead BMX compound, HCC-0010, to...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $780,034 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) to develop new chemoenzymatic methods for synthesizing infection-targeted PET radiotracers from the common oncologic tracer 2-deoxy-[18F]-fluoro-D-glucose ([18F]FDG). The goal is to increase access to new PET imaging tools for detecting Staphylococcus...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $817,405.00 to Colorado State University and its subrecipient, the University of Tennessee Health Science Center, to develop new drug regimens for treating tuberculosis (TB), including both drug-sensitive and multidrug-resistant strains. The key objectives are to: 1) manufacture and characterize inhalable dry...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $749,417 to support research focused on the development of novel bactericidal antibiotics targeting the lipoprotein transport pathway in Gram-negative bacteria. The research aims to diversify and improve an existing modular antibiotic platform to synthesize new candidate antibiotics with enhanced potency and...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program provides $256,922 to the California Institute of Technology (Caltech) to develop an adaptive framework for rapidly synthesizing and reconfiguring synthetic bacteriophages (phages) to counter antibiotic-resistant pathogens. The key objectives are to: 1) optimize an E....

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $741,917 to West Virginia University Research Corporation to develop therapeutic antibodies for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, with a focus on sepsis. The key objectives are to characterize the mechanism of action of a lead antibody candidate, formulate it into a multivalent...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop new antimicrobial agents and combination therapies to combat the growing threat of Gram-negative bacterial pathogens, specifically carbapenem-resistant Acinetobacter baumannii (CRAB) and Klebsiella pneumoniae (CRKP). The $2,308,174 award, with a performance period from August 2024 to May 2029, will fund three...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $288,360 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Biological Mimetics, Inc., a biotechnology firm in Frederick, Maryland. The funding supports the development of a novel vaccine candidate to provide protective immunity against multi-drug resistant Acinetobacter baumannii (MDR-AB), a significant public health threat. The Phase I project aims to (1) identify and characterize key immunogenic...